Christine Garvey
Known title: DirectorCIK: 0001073514
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Healthpeak Sets Q3 2026 Earnings Date and Declares Q4 Dividend. Healthpeak Properties announced the dates for its third‑quarter 2026 earnings release, conference call, and webcast. The company also declared a monthly common‑stock cash dividend for the fourth quarter of 2026. These updates give investors a schedule for upcoming earnings and confirm the firm’s continued dividend payments, which can influence trading activity.
Transaction History
| TOL | ▲ Buy | Option Exercise | 1,655 | $0 | 1/19/2026 | View on chart |
| TOL | ▼ Sell | Gift | 72 | $0 | 12/24/2025 | View on chart |
| TOL | ▼ Sell | Gift | 1,218 | $0 | 12/23/2025 | View on chart |
| TOL | ▼ Sell | Open Market | 770 | $92K | 7/14/2025 | View on chart |
| TOL | ▼ Sell | Gift | 25 | $0 | 3/31/2025 | View on chart |
| TOL | ▼ Sell | Gift | 47 | $0 | 3/28/2025 | View on chart |
| TOL | ▼ Sell | Gift | 188 | $0 | 3/13/2025 | View on chart |
| TOL | ▼ Sell | Gift | 566 | $0 | 2/25/2025 | View on chart |
| TOL | ▼ Sell | Open Market | 420 | $46K | 2/24/2025 | View on chart |
| TOL | ▲ Buy | Option Exercise | 2,007 | $0 | 1/19/2025 | View on chart |
| TOL | ▲ Buy | Option Exercise | 3,891 | $0 | 1/18/2025 | View on chart |
| TOL | ▼ Sell | Gift | 20 | $0 | 1/15/2025 | View on chart |
| TOL | ▼ Sell | Open Market | 204 | $26K | 12/30/2024 | View on chart |
| TOL | ▼ Sell | Gift | 40 | $0 | 12/26/2024 | View on chart |
| TOL | ▼ Sell | Open Market | 21 | $3K | 12/24/2024 | View on chart |
| TOL | ▼ Sell | Gift | 96 | $0 | 12/23/2024 | View on chart |
| TOL | ▼ Sell | Gift | 34 | $0 | 8/26/2024 | View on chart |
| TOL | ▼ Sell | Open Market | 170 | $21K | 5/24/2024 | View on chart |
| TOL | ▼ Sell | Gift | 170 | $0 | 3/15/2024 | View on chart |
| TOL | ▼ Sell | Gift | 277 | $0 | 2/22/2024 | View on chart |
| TOL | ▼ Sell | Open Market | 2,160 | $239K | 2/22/2024 | View on chart |
| TOL | ▼ Sell | Gift | 305 | $0 | 1/30/2024 | View on chart |
| TOL | ▲ Buy | Option Exercise | 2,921 | $0 | 1/20/2024 | View on chart |
| DOC | ▲ Buy | Grant | 8,193 | $0 | 4/28/2023 | View on chart |
| TOL | ▼ Sell | Open Market | 2,980 | $179K | 4/12/2023 | View on chart |
| TOL | ▼ Sell | Open Market | 125 | $7K | 3/2/2023 | View on chart |
| TOL | ▼ Sell | Gift | 34 | $0 | 2/28/2023 | View on chart |
| TOL | ▼ Sell | Gift | 715 | $0 | 2/23/2023 | View on chart |
| TOL | ▼ Sell | Open Market | 910 | $53K | 2/23/2023 | View on chart |
| DOC | ▼ Sell | Open Market | 1,200 | $31K | 2/22/2023 | View on chart |
| TOL | ▲ Buy | Option Exercise | 3,622 | $0 | 1/23/2023 | View on chart |
| TOL | ▼ Sell | Open Market | 200 | $10K | 12/28/2022 | View on chart |
| DOC | ▼ Sell | Open Market | 1,000 | $25K | 12/27/2022 | View on chart |
| DOC | ▼ Sell | Open Market | 1,860 | $46K | 11/16/2022 | View on chart |
| DOC | ▼ Sell | Gift | 302 | $0 | 8/16/2022 | View on chart |
| DOC | ▼ Sell | Gift | 102 | $0 | 5/23/2022 | View on chart |
| DOC | ▼ Sell | Gift | 152 | $0 | 5/4/2022 | View on chart |
| DOC | ▲ Buy | Grant | 5,258 | $0 | 4/28/2022 | View on chart |
| TOL | ▼ Sell | Gift | 717 | $0 | 2/24/2022 | View on chart |
| DOC | ▼ Sell | Gift | 190 | $0 | 2/23/2022 | View on chart |
| TOL | ▼ Sell | Gift | 1,038 | $0 | 1/24/2022 | View on chart |
| TOL | ▲ Buy | Option Exercise | 4,388 | $0 | 1/18/2022 | View on chart |
| TOL | ▼ Sell | Gift | 71 | $0 | 12/27/2021 | View on chart |
| TOL | ▼ Sell | Gift | 71 | $0 | 12/27/2021 | View on chart |
| DOC | ▼ Sell | Open Market | 300 | $10K | 11/19/2021 | View on chart |
| DOC | ▼ Sell | Open Market | 575 | $21K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Morgan Stanley initiates Toll Brothers coverage with Overweight rating
Morgan Stanley began covering Toll Brothers with an Overweight rating and a $159 price target. The firm positioned the homebuilder favorably compared to Berkshire Hathaway's preferred peers. This analyst action adds to a broader group of initiations reported this week, providing fresh institutional perspective on the stock.
Morgan Stanley initiates Toll Brothers coverage with Overweight rating. Morgan Stanley began covering Toll Brothers with an Overweight rating and a $159 price target. The firm positioned the homebuilder favorably compared to Berkshire Hathaway's preferred peers. This analyst action adds to a broader group of initiations reported this week, providing fresh institutional perspective on the stock.